mProX™ Human TLR7 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human TLR7 Stable Cell Line (S01YF-1023-PY213). Click the button above to contact us or submit your feedback about this product.
Jordan Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jordan Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The effective transduction of TLR7 and TLR8 in PANC 1 cells is depicted.
Western blot analysis confirmed enhanced TLR7 and TLR8 protein expression in transduced PANC1 cells. As controls, PANC1 cells transduced with an empty vector were employed. As a control for protein loading, a β-actin control was employed.
Ref: Grimmig, Tanja, et al. "TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer." International journal of oncology 47.3 (2015): 857-866.
Pubmed: 26134824
DOI: 10.3892/ijo.2015.3069
Research Highlights
Som, Avik. et al. "Percutaneous Intratumoral Immunoadjuvant Gel Increases The Abscopal Effect of Cryoablation for Checkpoint Inhibitor Resistant Cancer." Advanced healthcare materials, 2023.
Percutaneous cryoablation is a commonly used medical technique for treating both metastatic and primary cancer. While there have been rare cases of this treatment causing a regression of distant metastases, known as the "abscopal" effect, its effectiveness is often limited. One potential solution is the use of intratumoral immunoadjuvants, though current options require frequent injections and lack the ability to confirm successful drug delivery. To address these challenges, a new injectable gel-based formulation called "Imigel" has been developed. This thermoresponsive gel contains the FDA-approved TLR7 agonist imiquimod and a contrast agent for visualization under CT. By using a specialized copolymer gel, this treatment offers improved drug concentration and release rate, requiring only one injection. Further testing has shown its ability to significantly enhance the abscopal effect of cryoablation in aggressive colorectal and breast cancer dual tumor models. In these studies, responders saw complete regression of bilateral tumors in 90 days.
Som, Avik. et al. "Percutaneous Intratumoral Immunoadjuvant Gel Increases The Abscopal Effect of Cryoablation for Checkpoint Inhibitor Resistant Cancer." Advanced healthcare materials, 2023.
Pubmed:
37870153
DOI:
10.1002/adhm.202301848
Du, Yuxuan. et al. "Meta-analysis of the association between toll-like receptor gene polymorphisms and hepatitis C virus infection." Frontiers in microbiology, 2023.
The aim of this study was to examine the potential correlation between hepatitis C virus (HCV) infection and the toll-like receptor (TLR) 3/7 gene polymorphisms.
Du, Yuxuan. et al. "Meta-analysis of the association between toll-like receptor gene polymorphisms and hepatitis C virus infection." Frontiers in microbiology, 2023.
Pubmed:
37869679
DOI:
10.3389/fmicb.2023.1254805